All News

In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.

The man, in his 30s, has seen 2 specialists, received 2 diagnoses, and is now in the ED for persistent pain that is worsened by eye motion. Can you dx?

Black women seeking fertility care were less likely to report getting COVID-19 vaccine and were unsatisfied with how major health care systems handled the pandemic.

Your daily dose of clinical news you may have missed.

The novel approach to targeted obesity treatment could improve weight loss outcomes, suggest findings from ObesityWeek® 2022.

I have admitted infants to the hospital every winter for 40 years, yet I still don't have good answers for anxious parents watching their child struggling to breathe.

Your daily dose of clinical news you may have missed.

Study authors saw a positive dose-response relationship driven by hemorrhagic stroke in young adults who were moderate-to-heavy drinkers in their 20s and 30s.

The 2022 guidance covers acute, subacute, and chronic pain and replaces the 2016 guidelines.

Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.

Reddy talks about the value of A1c vs results of an OGTT for T2D diagnosis, about glycemic targets and patient safety, hyperglycemia during pregnancy, and more in our interview.

Your daily dose of clinical news you may have missed.

An OTC progestin only pill could potentially reduce the number of annual unintended pregnancies in the US by tens of thousands, a novel modeling study reveals.

AHA 2022: Chronic users of either e-cigarettes or traditional cigarettes had acute changes in cardiovascular function and performed worse on exercise stress testing than never users in new study.

Apixaban was associated with up to a 28% lower risk of GI bleeding vs the 3 other direct oral anticoagulants in the first large-scale comparative analysis.

RSV is back for the 2022-23 respiratory virus season and is unfamiliar to many. Click through this quick collection of myths already in circulation to prepare.

Your daily dose of clinical news you may have missed.

Semaglutide 2.4 mg (Wegovy) weight loss benefits in adolescents mirror those seen in adults, according to phase 3a trial findings presented at ObesityWeek® 2022.